Bengaluru-based Stelis Biopharma, the biotech arm of Strides Pharma Science, has raised USD 195 million by means of Series B and Series C funding, which the corporate will use to repay debt and for common company functions.
Source link
Bengaluru-based Stelis Biopharma, the biotech arm of Strides Pharma Science, has raised USD 195 million by means of Series B and Series C funding, which the corporate will use to repay debt and for common company functions.
Source link